GPT and Hepatic fibrosis: Our observations that cilofexor decreased liver fibrosis and reduced ALT, AST and TBIL in animals are in line with the findings of a 12-week, randomized, placebo-controlled phase II study in patients with PSC which clearly demonstrated that cilofexor was well tolerated and led to significant improvements in liver biochemistry and serum markers of cholestasis and liver fibrosis.15